Aviptadil is a Synthetic Peptide owned by Relief Therapeutics, and is involved in 14 clinical trials, of which 8 were completed, 3 are ongoing, and 3 are planned.

Aviptadil is a vasoactive intestinal polypeptide receptor 2 and vasoactive intestinal polypeptide receptor 1 agonist. Aviptadil is a vasodilator (it is able to enlarge small blood vessels) and lowers blood pressure. Endothelial cells contain a high density of vasoactive intestinal peptide (VIP) receptors. VIP has the capacity to relax the whole lungs in part by stimulating the generation of NO. This decrease the inflammatory processes by acting on the white blood cells (lymphocytes and monocytes) involved in the formation of the granulomas.

The revenue for Aviptadil is expected to reach a total of $152m through 2029. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Aviptadil NPV Report.

Aviptadil was originated by THERAMetrics and is currently owned by Relief Therapeutics.

Aviptadil Overview

Aviptadil is under development for the treatment of pulmonary sarcoidosis, coronavirus disease 2019 (COVID-19) pneumonia, checkpoint inhibitor-induced pneumonitis, chronic berylliosis, non-acute lung injury in coronavirus disease (COVID-19) and coronavirus disease (COVID-19) associated acute lung injury and coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome. The drug candidate is administered through inhalation and intravenous route. Aviptadil is a synthetic analogue of 28 amino acid vasoactive intestinal polypeptide. It acts by targeting VIP receptors Vasoactive Intestinal Polypeptide Receptor 1 and Vasoactive Intestinal Polypeptide Receptor 2. It was also under development for the treatment of idiopathic pulmonary fibrosis, acute lung injury and pulmonary arterial hypertension.

Relief Therapeutics Overview

Relief Therapeutics is a drug development company that offers clinical development of peptides and proteins of natural or engineered origin. Its pipeline drug candidates include PKU GOLIKE, ACER-001, APR-OD032, RLF-100, APR-TD011 and APR-TM011. The company offer its products in the therapeutic areas of rare metabolic disorders, rare pulmonary diseases, and rare connective tissue disorders, with particular emphasis on conditions with dermatological manifestations. It partners with academic institutions, healthcare researchers and patient support groups for product development and commercialization. Relief Therapeutics is headquartered in Geneve, Switzerland.

The company reported revenues of (Swiss Francs) CHF3.3 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was CHF34.3 million in FY2021, compared to an operating loss of CHF5.7 million in FY2020. The net loss of the company was CHF34.7 million in FY2021, compared to a net loss of CHF7.8 million in FY2020.

Quick View – Aviptadil

Report Segments
  • Innovator
Drug Name
  • Aviptadil
Administration Pathway
  • Inhalational
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Immunology
  • Infectious Disease
  • Respiratory
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.